Last updated: February 20, 2026
What is the drug associated with NDC 00904-7059?
NDC 00904-7059 corresponds to Ubrogepant, marketed as Ubrelvy. Ubrogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist approved by the FDA in 2019 for the acute treatment of migraine in adults.
What is the current market size for Ubrogepant?
The migraine treatment market has seen consistent growth driven by increasing migraine prevalence and the adoption of novel therapies like Ubrogepant. Key market data:
-
Global migraine drugs market: valued at approximately USD 3.2 billion in 2022.
-
Ubrogepant's market share: estimated at 8%-12% within the acute migraine treatment segment, given its relatively recent approval and growth trajectory.
-
Prescription trends: increased utilization through 2022 and 2023, especially among patients unresponsive or contraindicated to triptans.
-
Patient population:
-
Approx. 39 million adults in the U.S. suffer from migraines.
-
Approximately 15% have episodic migraines with moderate to severe intensity.
-
A subset of 10–15% of these patients are prescribed Ubrogepant annually, with prescriptions growing at a compound annual growth rate (CAGR) of about 18% since launch.
How does Ubrogepant compare to existing therapies?
| Therapy Type |
Examples |
Advantages |
Limitations |
| Triptans |
Sumatriptan, Rizatriptan |
Established efficacy; high market penetration |
Contraindicated in cardiovascular disease; contraindications limit use |
| NSAIDs |
Ibuprofen, Naproxen |
Over-the-counter; accessible |
Gastrointestinal side effects; less effective for severe migraines |
| CGRP Monoclonal Antibodies |
Erenumab, Fremanezumab |
Preventive use; sustained relief |
High cost; daily injections; delayed onset |
| Ubrogepant |
Ubrelvy |
No vasoconstriction risk; suitable for cardiovascular issues |
Higher per-dose cost; limited to acute treatment |
Ubrogepant offers an alternative for patients contraindicated for triptans, driving demand in specific segments.
What are the pricing dynamics for Ubrogepant?
Current pricing benchmarks
| Metric |
Approximate USD |
Source/Notes |
| Per prescription cost |
$450 - $600 |
Based on wholesale acquisition cost (WAC) and pharmacy claims data (Express Scripts, 2023) |
| Average monthly treatment cost |
$450 - $600 |
For acute migraine episodes requiring multiple doses |
| Per tablet (50 mg) |
$20 - $30 |
Pricing varies by pharmacy; sometimes higher for brand-name drugs |
| Insurance reimbursement rate |
~$200 - $400 |
After negotiated discounts and rebates |
Pricing comparison
-
Ubrogepant's price per dose significantly exceeds that of older therapies like NSAIDs but remains lower than biologic agents like CGRP monoclonal antibodies.
-
The high per-dose cost is driven by factor costs, patent protection, and limited competition.
What are the market projections for Ubrogepant?
Growth forecasts
| Year |
Projected prescriptions |
Market size (USD) |
Notes |
| 2023 |
~1.2 million |
$540 million |
Uptick in prescriptions attributed to broader awareness and expanded insurance coverage |
| 2025 |
~2.0 million |
$900 million |
Assumes continued CAGR of around 18-20% driven by increased adoption |
| 2030 |
~3.5 million |
$1.6 billion |
Expected market saturation and upward price adjustments |
Factors influencing growth
-
Broader acceptance for patients with cardiovascular contraindications to triptans.
-
Incorporation into migraine treatment guidelines.
-
Competitive dynamics including potential biosimilars or generics post-patent expiry.
-
Insurance coverage expansion, reducing out-of-pocket costs.
What are the potential pressures on future pricing?
-
Patent expiration around 2030 could introduce biosimilars or generics, exerting downward pressure.
-
Increased competition from emerging CGRP receptor antagonists and alternative migraine therapies.
-
Price sensitivity among payers leading to more aggressive negotiations.
-
Regulatory incentives to reduce drug costs could influence pricing strategies.
What are the key factors shaping market entry and pricing strategies?
-
Patent status: Patent protection until approximately 2030 limits generic competition.
-
Reimbursement policies: Payers favor cost-effective alternatives; negotiation leverage increases with volume.
-
R&D investment: Ongoing pipeline development could expand Ubrogepant’s indications, influencing pricing.
-
Market penetration: Depth of adoption among specialty neurologists and primary care providers determines revenue potential.
Summary of Price Projections
| Scenario |
Prescription volume |
Price per dose (USD) |
Market revenue (USD) |
Key assumptions |
| Base case |
2 million/year |
$500 |
$1 billion |
Steady growth in prescriptions; prices maintained |
| Conservative |
1.5 million/year |
$400 |
$600 million |
Increased biosimilar competition; price discounts |
| Aggressive |
3 million/year |
$600 |
$1.8 billion |
Rapid adoption; limited price concessions |
Key Takeaways
-
NDC 00904-7059 (Ubrelvy) operates within a growing migraine management market projected to reach USD 1.6 billion by 2030.
-
Current prices range from $450 to $600 per prescription, with higher costs per dose compared to conventional therapies.
-
Prescription growth is driven by unmet needs for patients contraindicated for triptans, supported by guideline integration.
-
Patent expiration around 2030 may introduce pricing and market share shifts via biosimilars or generics.
-
Market expansion depends heavily on insurance coverage, prescriber acceptance, and competing therapies.
Frequently Asked Questions
1. When does patent expiration for Ubrogepant occur?
Patent protection extends until approximately 2030, after which biosimilar or generic entries are possible.
2. How does insurance coverage influence Ubrogepant pricing?
Negotiated discounts and rebates reduce patient out-of-pocket costs; insurers often prefer cost-effective options, affecting effective prices and prescriptions.
3. Are there authorized generics for Ubrogepant?
No authorized generics exist currently; patent expiry may enable biosimilar development.
4. What are the major competitors to Ubrogepant?
Other CGRP receptor antagonists, triptans, NSAIDs, and preventive agents like CGRP monoclonal antibodies.
5. How likely is price reduction post-patent expiry?
High; market entrants typically lead to price competition, potentially reducing costs by 50% or more.
References
[1] IQVIA. (2023). Pharmaceutical Market Data.
[2] Express Scripts. (2023). Drug Price and Cost Data.
[3] FDA. (2019). Ubrogepant (Ubrelvy) Approval Announcement.
[4] MarketWatch. (2023). Global Migraine Drugs Market Analysis.
